gold investing Tectonic Metals Drills 2.41 g/t Au over 59.44 metres, Including 11.82 g/t Au over 10.67 metres and 39.96 g/t Au over 3.05 metres at Alpha Bowl, Flat Gold Project, Alaska
gold investing Tectonic Metals Appoints Eduard Epshtein as CFO, Bolstering Executive Team for Next Stage of Growth
gold investing Tectonic Metals Drills 1.40 g/t Au over 30.00 metres, Including 4.58 g/t Au over 4.50 metres, Extending Higher-Grade Corridor to 300 metres Vertical Depth at Chicken Mountain, Flat Gold Project, Alaska
gold investing Tectonic Metals Drills 5.09 g/t Au over 21.34 metres at Black Creek - Second Gold Centre Emerging at Flat Gold Project, Alaska
gold investing Tectonic Metals Advances Investor Engagement with Leadership Appointment and Announces Equity Grants
gold investing Tectonic Metals Strengthens Technical Leadership Team with Appointment of Vice President, Exploration
gold investing Tectonic Metals Launches 40,000 Metre, Five-Rig Drill Program to Advance High-Grade Gold Discoveries and Deliver Maiden Resource at Flat Gold Project, Alaska
gold investing Tectonic Raises Over C$92 Million; Completes Upsized Private Placement with Full Over-Allotment Exercised
gold investing Tectonic Metals Drills 272 Metres of 0.50 g/t Au and 277 Metres of 0.49 g/t Au; Confirms Bulk-Tonnage Potential at Heap-Leachable Chicken Mountain, Flat Gold Project, Alaska
GoldInxs Mining Corp. Closes Second Tranche of Upsized Non-Brokered Private Placement and Announces Board Changes
RENFORTH INTERSECTS BROAD NICKEL-COBALT AND ZINC-COPPER-SILVER MINERALIZATION IN VICTORIA UNDERCUT DRILLING, INCLUDING 118.0 m OF 0.081% Ni AND 10.9 m OF 0.544% Zn
CoTec Holdings Corp. Notes HyProMag USA Deployment of Mobile Inserma System, Extending Hard Disk Drive Processing to Customer Sites Across the United States
Renforth Successfully Intersects Gold in Both Drillholes Undercutting Surface Gold Results within the 2025 MRE Pit Shell at Wholly Owned Parbec Gold Deposit in Malartic, Quebec
Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site
